On December 14, 2023, Daniel Gelemanovic, CEO of Swisscann Tec AG, announced that the business has received official Good Manufacturing Practice (GMP) accreditation from Swissmedic. Swisscann’s steadfast dedication to upholding the highest standards in the medicinal cannabis sector is demonstrated by this incredible milestone.
Swisscann: dedication to quality
The GMP certification is evidence of Swisscann’s continuous commitment to providing outstanding experience in the quickly changing medical cannabis industry, not just a legal necessity. With this certification, Swisscann Tec AG is positioned as a leader in the industry. It proves its capacity to provide the highest-quality Active Pharmaceutical Ingredients (APIs). The company shows compliance to strict quality standards.
Daniel Gelemanovic expressed his appreciation to the entire Swisscann Tec AG team. He recognised their contribution in obtaining this respected certification. Their hard work and dedication have been crucial in elevating Swisscann to the forefront of the medical cannabis industry. Swisscann’s industry credibility will surely increase as a result of this certification. It will also create new opportunities for the business to further medical cannabis research and treatment.
Expected opportunities
Swisscann’s achievement of GMP certification establishes the company as a reliable supplier of pharmaceuticals that constantly fulfill the strictest regulations. The company’s commitment to excellence in the medical cannabis sector is further exemplified by its emphasis on producing Active Pharmaceutical Ingredients (APIs) of unparalleled quality. This illustrates more than just Swisscann Tec AG’s commitment to deliver high-quality medical solutions. It also emphasizes how important it is to further scientific knowledge and the use of cannabis-based treatments.
The medical marijuana market is still developing. Consequently, Swisscann Tec AG’s GMP certification represents a turning point in the business’ development. With this accomplishment, Swisscann is in a strong position to establish a standard for quality and innovation while making a major contribution to the expansion and growth of the medical cannabis industry.
In conclusion, Swisscann Tec AG’s achievement in obtaining GMP certification is evidence of its dedication to quality, innovation, and excellence within the medicinal cannabis sector. This accomplishment establishes the business as a leader in the industry and advances the use of medicinal cannabis for therapeutic purposes.